Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Esophageal Squamous Cell Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Tubulin Modulators

Antimitotic Agents

Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw

Paclitaxel plus carboplatin

Different radiotherapy dose in different groups.

radiotherapy

Kuaile Zhao, doctor

ying jia Deng, doctor

Jinjun C Ye, M.D.

Xiangpeng Zheng, M.D.

Xiangpeng Zheng

Kuaile Zhao, MD

Xiangpeng Zheng, doctor

So far, there is no specific clinical guideline for elderly patients (\>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx） or the chemoradiotherapy group (50.4Gy/28Fx；Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.

Up to now, definitive radiotherapy was major treatment plan for elderly ESCC patients. However, whether elective elderly patients can obtain survival benefits through chemoradiotherapy is not clear. Thus we design the clinical trail to answer the question.

Three hundred and twenty elderly patients with ESCC would be recruited. There are two stratification factors including 80 years old and lymph node metastasis. The patients in the chemoradiotherapy group were treated with paclitaxel (45mg/m2) and carboplatin (AUC=2) one cycle per week for five cycles.The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival. The life quality questionnaire included QlQ-C30 and OES-18.

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

The time between the start of the study treatment (Day 1) and death from any cause or last follow-up for patients alive at the end of the study.

Assess the quality of life through life quality questionnaire.

Record the radiation side effects including acute and late side effects.

The time between the start of the study treatment (Day 1) and death from tumor or last follow-up for patients alive at the end of the study.

Huadong Hospital

Jiangsu Cancer Institute & Hospital

Gansu Cancer Hospital

The First Affiliated Hospital of Xiamen University

Fujian Cancer Hospital

Taihe Hospital

Wuxi No. 4 People's Hospital

Ningbo No.2 Hospital

Fudan University

Carcinoma, Neuroendocrine

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Adenocarcinoma

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

Etoposide

Etoposide phosphate

Enzyme Inhibitors

Patients will be administered with etoposide plus carboplatin as first-line treatment.

Patients will be administered with paclitaxel plus carboplatin as first-line treatment.

etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.

etoposide plus carboplatin

Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.

Zhen Zhou, MD

The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.

The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.

In addition, gene spectrum detection and Mini-PDX are applied for validation of pharmacodynamic.

Results of clinical trials and pharmacodynamic test will be analyzed to provide evidence for the precise treatment for LCNEC.

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study

Interval from randomization to disease progression, or untolerated toxicity

Percentage of complete response and partial response

Shanghai Chest Hospital

Chief Physician

Skin and Connective Tissue Diseases

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Diseases

Skin Diseases

Anti-Infective Agents

Epirubicin

Anti-Bacterial Agents

Antibiotics, Antitubercular

The control arm receive the paclitaxel plus epirubicin

the experimental arm which receive the paclitaxel combined with carboplatin

Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.

1 cycle = 21days 2-6cycles

Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.

1 cycle = 21days

2-6cycles

Paclitaxel and epirubicin

ZHANG Pin, BD

YIN Yi, BD

This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.

It is know that triple-negative breast cancer(TNBC) is more aggressive than non-triple negative breast cancer in both pathological features and clinical prognosis,and there is no standard chemotherapy regimens especially for TNBC. NCCN guidelines recommends Paclitaxel or Epirubicin based regimens as the preferred regimens both for the adjuvant chemotherapy and the treatment of Recurrence and Metastatic breast cancer.The combination of these two drugs is considered as a strong arrangement and therefore,is common used in Triple negative breast cancer patients because of its poor prognosis.

According to the results of some retrospective studies, platinum-based chemotherapy regimens showed a promising sensitive to Triple negative breast cancer patients compared with regimens without platinum.

This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Phase IIb Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Epirubicin as Neoadjuvant Treatment in Locally Advanced Triple-negative Breast Cancer

After patients complete the neoadjuvant chemothreapy and receive the surguries,we can get their pathology ，and compare the pCR（pathological complete remission）rates of two amrs

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)	NCT04519905	Esophageal Squa... Chemoradiothera... Survival	Paclitaxel plus... radiotherapy	76 Years -	Fudan University
Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma	NCT02943798	Pulmonary Large...	etoposide plus ... Paclitaxel plus...	18 Years - 75 Years	Shanghai Chest Hospital
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer	NCT01276769	Triple Negative...	Paclitaxel plus... Paclitaxel and ...	18 Years - 70 Years	ChineseAMS

Spots Global Cancer Trial Database for paclitaxel plus carboplatin